Altoida and Ionian University Investigate Breakthrough Software Device for Parkinson's Disease Diagnosis
Retrieved on:
Monday, October 25, 2021
Data Management, Other Science, Seniors, Technology, Research, Managed Care, Other Health, Consumer, Pharmaceutical, Mental Health, Genetics, Fitness & Nutrition, Clinical Trials, Biotechnology, Other Education, University, Software, Health, Education, Science, DBm, Diagnosis, Technology, LinkedIn, Neurodegeneration, Neuron, AR, Twitter, Ionian University, Partnership, Patient, FDA, TUM Department of Informatics, Bioinformatics, Parkinson's disease, Risk, Intelligence, Life, Smartphone, Biomarker, Health, Artificial intelligence, Therapy, Department, Medical device, Medical imaging
Altoida, Inc. the worlds leading Precision Neurology company, announced a collaboration with the Bioinformatics and Human Electrophysiology Laboratory (BiHELab), Department of Informatics at Ionian University.
Key Points:
- Altoida, Inc. the worlds leading Precision Neurology company, announced a collaboration with the Bioinformatics and Human Electrophysiology Laboratory (BiHELab), Department of Informatics at Ionian University.
- The collaboration will investigate Altoidas medical device, an FDA Breakthrough Device being developed for early diagnosis and monitoring of Alzheimers disease, for early diagnosis and prediction of Parkinsons disease onset.
- In that time, Altoida and BiHELab will apply and Altoidas technology to analysis of Parkinsons disease progression and evaluate its efficacy in diagnosing Parkinsons in the preclinical phase.
- For Parkinsons patients, accurate prediction and early diagnosis could enable intervention before the extensive damage of dopaminergic neurons occurs."